Cryptic Susceptibility to Penicillin/β-Lactamase Inhibitor Combinations in Emerging Multidrug-Resistant, Hospital-Adapted Staphylococcus Epidermidis Lineages

Global spread of multidrug-resistant, hospital-adapted Staphylococcus epidermidis lineages underscores the need for new therapeutic strategies. Here we show that many S . epidermidis isolates belonging to these lineages display cryptic susceptibility to penicillin/β-lactamase inhibitor combinations under in vitro conditions, despite carrying the methicillin resistance gene mecA . Using a mouse thigh model of S . epidermidis infection, we demonstrate that single-dose treatment with amoxicillin/clavulanic acid significantly reduces methicillin-resistant S . epidermidis loads without leading to detectable resistance development. On the other hand, we also show that methicillin-resistant S . epidermidis is capable of developing increased resistance to amoxicillin/clavulanic acid during long-term in vitro exposure to these drugs. These findings suggest that penicillin/β-lactamase inhibitor combinations could be a promising therapeutic candidate for treatment of a high proportion of methicillin-resistant S . epidermidis infections, although the in vivo risk of resistance development needs to be further addressed before they can be incorporated into clinical trials.